Metronidazole Articles
Medarex in up to $225M C. diff deal with Merck & Co
22 April 2009
Japan stock market week to March 23, 2009
30 March 2009
Takeda files Japanese NDA for H. Pylori combo
30 March 2009
US court sentences fake Viagra dealer
28 July 2008
Telvancin non-inferior in HAP/VAP studies
17 December 2007
Cosmo's Rifamycin non-inferior to Normix in Ph II study
10 December 2007
UPDATE: ICAAC 2006 sees strong data on next-gen antibiotics: Tygacil, ceftaroline, cethromycin
9 October 2006
Strong efficacy data for S-P's Avelox
9 October 2006
3M explores options for pharma business
10 April 2006
Dow gets US FDA OK for MetroGel
18 July 2005
UPDATE: Warner Chilcott's Femtrace OKed in USA
30 August 2004
India revises 22 bulk drug prices
2 June 2003
Axcan's Helicide approved in Canada
31 March 2003
FDA rejects Axcan's Helicide for H pylori
19 August 2002
Axcan to acquire France's Lacteol
15 April 2002
UK nurse Rxers' list widens to antibiotics
25 February 2002
India's NPPA revises 81 formulation prices
14 January 2002
Axcan files for approval of Helicide in USA and Canada
5 October 2001
Analysts expectant on future prospects for Canada's Axcan Pharma
13 February 2001
Aventis seeks buyer for stake in R-P India
28 November 2000
P&U receives FDA OK for Cleocin
17 August 1999
Losses deepen for Scotland's Core Group
29 March 1999
Drug development news in brief
10 March 1999
Selecting Diseases Suitable For OTC Treatment
4 December 1998
Drugs And Media: Making And Controlling The News
3 April 1998
Searle's Flagyl ER Set For 1Q98 Launch
18 December 1997
US H2 Blocker Boom Forecast To Slow Down
27 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Bradley Pharma Settles Patent Dispute With P&G
4 November 1996
Triple Therapy For H Pylori
28 October 1996
P&G To Launch Low-Cost Helicobacter Regimen In USA
2 September 1996
Rhone-Poulenc Rorer's "Year Of Firsts"
5 February 1996
Ulcer Therapy Market Set For Transformation
18 December 1995
"Only H pylori And NSAIDs Cause Ulcers"
25 September 1995
Glaxo Wellcome's Pylorid Launched In First Market
18 September 1995
P & G NDA for bismuth....
7 August 1995
Recordati Sales Boost From Rx Abroad, Italian OTCs
7 August 1995
Merck pipline report
3 July 1995
Searle's Flagyl gains US FDA approval
22 May 1995
Modern Triple Therapy For H Pylori
8 May 1995
Recordati Earnings Increase As Sales Decline
10 April 1995
Rulid For Helicobacter Eradication
3 April 1995
Rozex Launch In UK
23 January 1995
Helicobacter pylori Eradication Halts Gastric Cancer
28 November 1994
Zantac Approved For Eradication Therapy In UK
21 November 1994
Eradication Therapy For Helicobacter Pylori
10 October 1994
GALDERMA TO SUPPLY METROGEL FOR FREE
11 July 1994
FIRST CLINICAL DATA FOR GLAXO'S GR122311X
6 June 1994
FUTURE LOOKS ROSY FOR LOSEC H PYLORI COMBO
4 April 1994
COST-CUTTING IN SPANISH HEALTH CARE
7 March 1994
NIH ISSUES CONSENSUS STATEMENT ON H PYLORI
14 February 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
CHINESE FOREIGN INVESTMENT OPPORTUNITIES
6 December 1993
CHINESE FOREIGN INVESTMENT OPPORTUNITIES
6 December 1993
CURATEK AGREEMENT
29 November 1993
PHARMA RESOURCES RELAUNCHES DRUGS
22 November 1993
UK INDUSTRY CODE OF PRACTICE REVIEW
19 July 1993
GALDERMA ACQUISITION
12 July 1993
NEW DATA ON LOSEC IN ULCER RELAPSE
12 April 1993
GLOBAL SALES OF H2 BLOCKERS TO DECLINE?
1 March 1993
ULCER STUDY NO THREAT TO ULCER DRUG FIRMS
22 February 1993
NEW H PYLORI RECOMMENDATIONS
12 October 1992
RESISTANCE ENSURES AUGMENTIN'S FUTURE
15 June 1992
H PYLORI TREATMENT: A ROLE FOR OMEPRAZOLE?
25 May 1992
STUDY SUPPORTS ULCER/H PYLORI HYPOTHESIS
11 May 1992
AUGMENTIN AS EFFECTIVE AS COMBO REGIMENS
4 May 1992
SANDOZ' METROGEL LAUNCHED IN UK
27 April 1992
CURATEK FILES NDA FOR METROGEL-V
20 April 1992
BULLETIN REVIEWS NEW TOPICAL PRODUCTS
9 March 1992
Showing 1-74 of 74 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
